Skip to main content
Premium Trial:

Request an Annual Quote

Bionomics and Australian Institute Sign Epilepsy Gene, CNS Research Pact

NEW YORK, Feb. 25 - Australian genomics-based drug discovery firm Bionomics has established a research collaboration in the area of epilepsy and CNS disorders with the Howard Florey Research Insititute in Melbourne, the company said today.


Bionomics, based in Adelaide, Australia, focuses on discovering and characterizing disease-related genes, especially in breast cancer, epilepsy, and angiogenesis.


The Howard Florey Institute, headed up by professor Frederick Mendelsohn, focuses its research on brain and peripheral nervous system areas, including neurochemistry, neurobiology, and neuroinformatics.



The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.